Gilead Sciences Inc (GILD)

71.01
NASDAQ : Health Care
Prev Close 71.57
Day Low/High 70.58 / 72.00
52 Wk Low/High 70.58 / 103.10
Avg Volume 9.77M
Exchange NASDAQ
Shares Outstanding 1.32B
Market Cap 94.29B
EPS 12.40
P/E Ratio 6.65
Div & Yield 1.88 (2.60%)

Latest News

Jump on Harley Davidson, but Stay Away From Costamare: 'Mad Money' Lightning Round

Jump on Harley Davidson, but Stay Away From Costamare: 'Mad Money' Lightning Round

Jim Cramer likes Harley and Enterprise Products Partners, but says stay away from Costamare and Achaogen.

Earnings, Not Just the Trump Rally, Drive Stocks: Cramer's 'Mad Money' Recap (Wednesday 1/18/17)

Earnings, Not Just the Trump Rally, Drive Stocks: Cramer's 'Mad Money' Recap (Wednesday 1/18/17)

Jim Cramer explains how bullish comments from one semiconductor equipment maker lifts shares throughout the sector.

Buy Stocks You Think Will Survive 'Nuclear Winter'

Buy Stocks You Think Will Survive 'Nuclear Winter'

If you buy right, time and value should do most of the heavy lifting for you.

Biotech Sector to See M&A, Earnings Action

Biotech Sector to See M&A, Earnings Action

Deals already are popping up, and we'll soon have earnings reports from the industry giants.

5 Things You Must Know Before the Market Opens Thursday

5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures and shares in London and Asia fall Thursday after Donald Trump offers few details on his policies during his first press conference since winning the U.S. election.

European Commission Grants Marketing Authorization For Gilead's Vemlidy® (Tenofovir Alafenamide, TAF) For The Treatment Of Chronic Hepatitis B Virus Infection

European Commission Grants Marketing Authorization For Gilead's Vemlidy® (Tenofovir Alafenamide, TAF) For The Treatment Of Chronic Hepatitis B Virus Infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for Vemlidy ® (tenofovir alafenamide, TAF) 25 mg, a once-daily tablet for the treatment of chronic...

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Gilead Awards More Than $22 Million In Grants To Support HIV Cure Research

Gilead Awards More Than $22 Million In Grants To Support HIV Cure Research

Gilead Sciences, Inc. (Nasdaq:GILD) today announced the recipients of its HIV cure grants program, a fund totaling more than $22 million, which will support 12 new HIV cure research projects.

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.

5 Stocks Profit-Takers Jumped On in December, says TD Ameritrade

5 Stocks Profit-Takers Jumped On in December, says TD Ameritrade

The S&P 500 rose about 2% in December as the Trump rally rolled on, but that didn't stop individual investors from locking in gains according to a TD Ameritrade index.

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

Nasdaq Hits Records Even as Crude Selloff Sours Rest of Market

A selloff in crude oil proves another roadblock in the Dow Jones Industrial Average's pursuit of 20,000.

Allergan Is a Blueprint for Gilead

Allergan Is a Blueprint for Gilead

At least, that's the case when it comes to a technical trade.

Allergan, Google, Oaktree Capital: Doug Kass' Views

Allergan, Google, Oaktree Capital: Doug Kass' Views

Doug Kass shares his thoughts on how January has a lot of nonsense, and reviews his investment troops.

Alphabet, Apple, Allergan: Doug Kass' Views

Alphabet, Apple, Allergan: Doug Kass' Views

Doug Kass shares his thoughts on the deepening of retail stocks' weakness and the Amazon Effect.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Here Are 6 Things to Watch Out for at J.P. Morgan's Healthcare Conference Next Week

Here Are 6 Things to Watch Out for at J.P. Morgan's Healthcare Conference Next Week

Next week the J.P. Morgan Healthcare Conference becomes the hottest spot in biotech and pharma.

5 Toxic Stocks to Watch

5 Toxic Stocks to Watch

Watch out for these stocks as we start 2017.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Here's Why You Should Sell Gilead, PPG, 3 More Toxic Stocks Before It's Too Late

Here's Why You Should Sell Gilead, PPG, 3 More Toxic Stocks Before It's Too Late

Avoiding the worst-performing stocks could boost your returns far more than picking the very best ones in the year ahead.

Beaten-Down Gilead Is My Top 2017 Pick

Beaten-Down Gilead Is My Top 2017 Pick

Shares are dirt cheap as revenues and profits have grown.

Here's What to Look for at the J.P. Morgan Healthcare Conference

Here's What to Look for at the J.P. Morgan Healthcare Conference

The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017

Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.

Gilead Sciences Is Surging -- Here's How to Trade It

Gilead Sciences Is Surging -- Here's How to Trade It

Gilead Sciences is a top gainer in the Nasdaq 100 with the help of a 3.2% rally.

Alessandro Riva, MD, To Join Gilead As Senior Vice President, Hematology And Oncology Therapeutic Area Head

Alessandro Riva, MD, To Join Gilead As Senior Vice President, Hematology And Oncology Therapeutic Area Head

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Alessandro Riva, MD, will join the company as Senior Vice President, Hematology and Oncology Therapeutic Area Head.

Biotech Should Witness M&A's Return in 2017

Biotech Should Witness M&A's Return in 2017

Drug giants with money to spend and a friendlier regulatory environment should spur deals.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Starbucks, Allergan, Amazon: Doug Kass' Views

Starbucks, Allergan, Amazon: Doug Kass' Views

Doug Kass shares his thoughts on how 2017 will be the year of 'the Dude.'